Coronavirus disease 2019 vaccination-related pericarditis: a single tertiary-center experience.
J Cardiovasc Med (Hagerstown)
; 23(12): 779-783, 2022 Dec 01.
Article
in English
| MEDLINE | ID: covidwho-2054847
ABSTRACT
AIMS:
Vaccination represents a cornerstone of prevention in the COVID-19 pandemic. Rare adverse events including acute pericarditis and myopericarditis have been reported.METHODS:
All consecutive patients referred to our referral center for pericardial diseases following COVID-19 vaccination from 1 April 2021 to 15 April 2022 were included. Acute pericarditis and myopericarditis were diagnosed according to ESC guidelines. Patients with SARS-CoV-2 infection were excluded from the study.RESULTS:
Twenty-four patients (79% men) aged 39.7â±â19.8âyears were referred to our center with pericarditis after receiving COVID-19 vaccination. Thirteen (54%) patients were diagnosed with myopericarditis. The mean time between vaccination and symptoms onset was 7.0â±â4.9âdays, and the most frequent symptom was pericarditic chest pain (83%). Respectively, 50 and 33% of patients presented after the second and the third dose of the vaccine. Almost all patients were treated with both nonsteroidal anti-inflammatory drugs and colchicine. Five patients (21%) experienced a recurrence of pericarditis. No patient died or developed constrictive pericarditis. Mean follow-up was 8.0â±â3.2âmonths.CONCLUSION:
COVID-19 vaccine-related pericarditis typically manifest with mild clinical signs, in young male individuals, a few days after the second or third vaccine dose and are commonly characterized by a rapid complete recovery.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pericarditis
/
COVID-19
/
Myocarditis
Type of study:
Cohort study
/
Diagnostic study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
Language:
English
Journal:
J Cardiovasc Med (Hagerstown)
Journal subject:
Vascular Diseases
/
Cardiology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS